Search results for "REcombinant protein"

showing 10 items of 707 documents

Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C

2003

Occult HBV infection in subjects with chronic hepatitis C is related to more severe disease outcome. It has been suggested that it might reduce sensitivity to antiviral treatment.To assess in HBsAg negative subjects with chronic hepatitis C any effect of the presence of HBV genomes in the liver on the early kinetics of HCV-RNA under PEG-IFN plus ribavirin.Twenty-two anti-HCV and HCV-RNA positive subjects, with biopsy-proven chronic hepatitis C (M/F 15/7; 50 +/- 8.6 years, 16 genotype 1b) were given PEG-IFN alpha 2b 1.0 microg qw plus ribavirin (800 to 1,200 mg daily according to body weight) for an intended 52 week period. Early virological response was assessed over the first 4 weeks of th…

AdultMaleHepatitis B viruspegylated interferon-alphaGenotypeBiopsyHepacivirusInterferon alpha-2Virus ReplicationAntiviral AgentsPolyethylene GlycolsHepatitis B AntibodieRibavirinchronic hepatitis CHumansHepatitis B AntibodiesAntiviral AgentHepaciviruoccult HBV infection; chronic hepatitis C; pegylated interferon-alpha; viral dynamics; treatment responseoccult HBV infectiontreatment responseInterferon-alphaAlanine TransaminaseHepatitis B viruHepatitis C AntibodiesHepatitis C ChronicMiddle AgedRecombinant ProteinViral LoadHepatitis Bviral dynamicsRecombinant ProteinsTreatment OutcomeLiverDNA ViralRNA ViralDrug Therapy CombinationFemaleHepatitis C AntibodieHuman
researchProduct

Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis

1992

Hepatitis C virus (HCV) replication was assessed before and during alpha-interferon (IFN) treatment in 22 anti-HCV positive patients with posttransfusion or sporadic chronic hepatitis (CH). Eleven patients were “responders” and 11 patients “non-responders” to IFN. Thirteen anti-HCV negative healthy subjects and five anti-HCV negative patients with autoimmune CH served as controls. Serum HCV-RNA was detected by the polymerase chain reaction (PCR) in all untreated anti-HCV positive patients but in none of the anti-HCV negative subjects. PCR primers from the 5′-non-coding (NC) region were more sensitive than primers from a non-structural (NS5) region in detecting HCV-RNA (21/22, 95% vs. 7/22, …

AdultMaleHepatitis C virusMolecular Sequence DataDNA Single-StrandedAlpha interferonHepacivirusAutoimmune hepatitisInterferon alpha-2Virus Replicationmedicine.disease_causePolymerase Chain ReactionSensitivity and SpecificityVirusInterferonVirologymedicineHumansHepatitis AntibodiesViremiaBase Sequencebiologybusiness.industryInterferon-alphavirus diseasesHepatitis C AntibodiesMiddle Agedmedicine.diseaseHepatitis CVirologyRecombinant ProteinsTiterInfectious DiseasesChronic DiseaseImmunologybiology.proteinRNA ViralFemaleViral diseaseAntibodybusinessmedicine.drugJournal of Medical Virology
researchProduct

Circulating intercellular adhesion molecule-1 in chronic hepatitis C patients with normal or elevated aminotransferase before and after alpha-interfe…

2001

<i>Objectives:</i> Intercellular adhesion molecule-1 (ICAM-1) plays a fundamental role during liver inflammation. In fact, weak ICAM-1 expression is physiologically restricted to the endothelium of portal vessels and to sinusoidal lining cells, but it becomes markedly evident on sinusoidal lining cells and at the surface of hepatocytes during inflammatory liver diseases. The aim of this study was to evaluate the behaviour of soluble ICAM-1 (sICAM-1) in chronic hepatitis C (CH-C) patients with persistently normal aminotransferase in comparison with patients with CH-C and elevated aminotransferase, and its changes during α-interferon (IFN) therapy. Immunohistochemical localization…

AdultMaleIntercellular Adhesion Molecule-1Alpha interferonInflammationInterferon alpha-2BiologyChronic hepatitis CAntiviral Agentsα-InterferonLiver diseaseChronic hepatitisVirologymedicineHumansAspartate Aminotransferasesα interferonInterferon-alphaAlanine TransaminaseAdhesionIntercellular adhesion molecule-1Hepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsInfectious DiseasesImmunologyCancer researchFemalemedicine.symptomLiver diseaseIntracellular
researchProduct

Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin

2012

It is unclear whether the current threshold for 'high' hepatitis C virus (HCV) RNA level (800,000 IU/mL) is optimal for predicting sustained virological response (SVR). We retrospectively analysed pretreatment HCV RNA levels and SVR rates in 1529 mono-infected and 176 HIV-HCV co-infected patients treated with peginterferon alfa-2a (40 kD) plus ribavirin. We improved the threshold for differentiating low and high viral load by fitting semiparametric generalized additive logistic regression models to the data and constructing receiver operating characteristics curves. Among HCV genotype 1 mono-infected patients, the difference in SVR rates between those with low and high baseline HCV RNA leve…

AdultMaleInterferon-alphaAlanine TransaminaseHepacivirusMiddle AgedViral LoadAntiviral AgentsHepatitis CRecombinant ProteinsPolyethylene GlycolsLogistic ModelsTreatment OutcomeROC CurveRibavirinHumansRNA ViralDrug Therapy CombinationFemalehepatitis CRetrospective Studies
researchProduct

In vitro treatment with interleukin-2 normalizes type-1 cytokine production by lymphocytes from elderly

2000

The term immunosenescence is taken to mean the deterioration of immune function seen in elderly, which is manifested in increased susceptibility to infectious diseases, neoplasias, and autoimmune diseases. It is only recently that we have begun to understand the cellular and molecular changes involved. Of special interest in this regard are observations of a decline in synthesis of Type-1 cytokines which predisposes to diminished cell mediated immunity. We have evaluated the production of type 1 cytokines in old and young donors either in presence or in absence of recombinant interleukin-2 (rIL-2). Lymphocytes were stimulated with plastic bound anti-CD3 and after 48 h the supernatants were …

AdultMaleInterleukin 2Agingmedicine.medical_specialtymedicine.medical_treatmentImmunologyIn Vitro TechniquesBiologyToxicologylaw.inventionInterferon-gammaImmune systemlawInternal medicinemedicineHumansImmunology and AllergyAgedAged 80 and overPharmacologyGeneral MedicineImmunosenescenceMiddle AgedTh1 CellsInterleukin-12Recombinant ProteinsCell mediated immunityIn vitroEndocrinologyCytokineImmunologyRecombinant DNACytokinesInterleukin-2Femalemedicine.drug
researchProduct

Ocular Changes in Patients With Mucopolysaccharidosis I Receiving Enzyme Replacement Therapy

2007

Objective To describe the progression of ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy. Methods Three male and five female patients with mucopolysaccharidosis I were followed up for 4 years while undergoing enzyme replacement therapy with α-L-iduronidase (Aldurazyme). Visual acuity, corneal clouding, intraocular pressure, ophthalmoscopy, and optic disc measurements were performed yearly. Results Vision remained stable in 5 patients and deteriorated by at least 2 Snellen lines in 3 patients. Deterioration in 2 of these patients was related to progressive corneal clouding. Visual acuities improved in 1 patient after bilateral penetrating keratopl…

AdultMaleIntraocular pressuremedicine.medical_specialtyVisual acuityAdolescentgenetic structuresMucopolysaccharidosis Imedicine.medical_treatmentOptic DiskVisual AcuityCorneal DiseasesIduronidaseDouble-Blind MethodOptic Nerve DiseasesMucopolysaccharidosis IHumansMedicineChildInfusions IntravenousPapilledemaIntraocular PressureCorneal transplantationbusiness.industryEnzyme replacement therapyRecombinant Proteinseye diseasesSurgeryOphthalmoscopyOphthalmologymedicine.anatomical_structureDisease ProgressionOptic nerveFemalesense organsmedicine.symptombusinessOptic discArchives of Ophthalmology
researchProduct

Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma

2013

Background: Neutropenia and its complications represent one of the principal dose-limiting toxicity issues in chemotherapeutic regimens for soft tissue sarcoma. Prophylactic granulocyte colony-stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN). The correct timing of G-CSF administration should be considered in order to optimize the prophylactic treatment. Patients and Methods: Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9. The proportion of patients experiencing FN and G4 neutropenia was considered. Results: A total of 36 patient…

AdultMaleNeutropeniaSettore MED/06 - Oncologia MedicaAntineoplastic AgentsSarcomaSoft Tissue Neoplasmslenograstrim sarcoma neutropeniaMiddle AgedLenograstim Febrile Neutropenia Soft tissue sarcomaLenograstimRecombinant ProteinsYoung AdultAdjuvants ImmunologicGranulocyte Colony-Stimulating FactorHumansFemaleIfosfamideAgedEpirubicin
researchProduct

CD4-mediated regulatory T-cell activation inhibits the development of disease in a humanized mouse model of allergic airway disease

2012

Background Based on their potency to control allergic diseases, regulatory T (Treg) cells represent a promising target for novel strategies to interfere with allergic airway inflammation. We have previously demonstrated that stimulation of the CD4 molecule on human Treg cells activates their suppressive activity in vitro and in vivo . Objective We sought to determine the effect of CD4-mediated Treg-cell activation on pulmonary inflammation in a humanized mouse model of allergic airway inflammation. Methods PBMCs obtained from donors allergic to birch pollen or from healthy donors were injected into NOD-severe combined immunodeficiency γc −/− mice, followed by allergen airway challenges and …

AdultMaleRegulatory T cellAHRImmunologychemical and pharmacologic phenomenaInflammationMice SCIDHIV Envelope Protein gp120pulmonary inflammationmedicine.disease_causeT-Lymphocytes Regulatoryregulatory T cellsMiceImmune systemAllergenRespiratory HypersensitivitymedicineAnimalsHumansImmunology and AllergyImmunodeficiencySensitizationSevere combined immunodeficiencybusiness.industryhemic and immune systemsPneumoniaMiddle Agedrespiratory systemmedicine.diseaseRecombinant ProteinsHumanized animal modelrespiratory tract diseasesDisease Models Animalmedicine.anatomical_structureCD4 AntigensImmunologyHumanized mouseLeukocytes MononuclearFemaleInterleukin-4Bronchial Hyperreactivitymedicine.symptombusinessJournal of Allergy and Clinical Immunology
researchProduct

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

2002

Background Treatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C. Methods A total of 1121 patients were randomly assigned to treatment and received at least one dose of study medication, consisting of 180 μg of peginterferon alfa-2a once weekly plus daily ribavirin (1000 or 1200 mg, depending on body weight), weekly peginterferon alfa-2a plus daily pl…

AdultMaleSimeprevirmedicine.medical_specialtyGenotypeTaribavirinHepacivirusInterferon alpha-2Antiviral AgentsGastroenterologyPolyethylene GlycolsTelaprevirchemistry.chemical_compoundstomatognathic systemhemic and lymphatic diseasesInternal medicineBoceprevirRibavirinHumansMedicinebusiness.industryRibavirinInterferon-alphavirus diseasesGeneral MedicineHepatitis C ChronicRecombinant Proteinsdigestive system diseasesInterleukin 28BchemistryImmunologyRNA ViralPeginterferon alfa-2bDrug Therapy CombinationFemalebusinesstherapeuticsmedicine.drugPeginterferon alfa-2a
researchProduct

Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C.

2011

Background Genotype 1 (G1) chronic hepatitis C (CHC) patients achieving a rapid virological response (RVR) on pegylated interferon (PEG-IFN) plus ribavirin have a high chance of sustained virological response (SVR), influenced by IL28B status, viral load, fibrosis and insulin resistance. We assessed whether 25-hydroxyvitamin D (25[OH]D) serum levels are linked to RVR and can be used together with IL28B to construct a pretreatment model to predict RVR. Methods A total of 117 consecutive patients with G1 CHC were evaluated by biopsy and anthropometric and metabolic measurements. 25(OH)D serum levels were measured by HPLC. IL28B rs12979860 and rs8099917 polymorphisms were also evaluated. All p…

AdultMaleStandard of careGenotypeHepacivirusAntiviral AgentsPolymorphism Single NucleotidePolyethylene GlycolsVirological responsechemistry.chemical_compoundChronic hepatitisPegylated interferonRisk FactorsGenotypeVitamin D and neurologyMedicineHumansPharmacology (medical)Vitamin DPharmacologybusiness.industryRibavirinInterleukinsInterferon-alphaStandard of CareHepatitis C ChronicMiddle AgedViral LoadRecombinant ProteinsInfectious DiseasesTreatment OutcomechemistryImmunologyFemaleInterferonsbusinessmedicine.drugAntiviral therapy
researchProduct